drugset / Trial / NCT05545020

Trivalent Chromium Treatment for Rheumatoid Arthritis

NCT05545020

Phase 2/3 Completed 60 enrolled Alexandria University
RandomizedParallel-groupOpen-labelTreatment

Summary

Trivalent chromium has shown good results in abolishing inflammation and had a successful result in treating animal model of rheumatoid arthritis. In addition to that, trivalent chromium lacks many side effects which are related to the already known medications of the disease. So this study aims to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients.

Timeline

Start
2022-12-25
Primary completion
2024-01-13
Completion
2024-01-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Baricitinib Small molecule
Comparator Trivalent chromium Unknown

Indications